Back to discover

Protein / target

SLAM family member 7

Encoded bySLAMF7Q9NQ25Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Antibody-tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Identical protein binding

Strongest disease association

Multiple Sclerosis

Via encoding gene SLAMF7 · Genetic evidence · score 0.57

Therapeutic position

Established drug target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family.

View complete UniProt function annotation

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Also acts inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of pro-inflammatory cytokines (PubMed:23695528)

Subcellular location

Membrane
Domains and Gene Ontology detail (11)

Domains & features

Ig-like V-typeIg-like C2-type

Gene Ontology

  • Cexternal side of plasma membrane
  • Cplasma membrane
  • Fidentical protein binding
  • Padaptive immune response
  • Pcell adhesion
  • Pimmune response
  • Pnatural killer cell activation
  • Pnatural killer cell mediated cytotoxicity
  • PT cell activation

335 aa · 37 kDa · 7 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO
View supporting evidence

Immune signalling

  • ·adaptive immune response
  • ·immune response
  • ·T cell activation
View underlying pathways (1)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CD48SH2D1BCD2SH2D1AFCGR3ACD38FCGR3BCD244KLRK1SLAMF1SLAMF7

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Multiple Myeloma1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

elotuzumab
Narrow target profileApprovedInhibitor

SLAM family member 7 inhibitor

Indicated for Multiple Myeloma, Neoplasms

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SLAMF7

Gene-level evidence surfaced through the gene SLAMF7that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Multiple Myeloma
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Multiple Sclerosis
0.58Moderately supported

Genetic evidence dominant · Open Targets 0.35

Epstein-Barr Virus Infections
0.53Moderately supported

Genetic evidence dominant · Open Targets 0.32

Neoplasms
0.53Moderately supported

Clinical evidence dominant · Open Targets 0.40

Rotator cuff syndrome
0.46Limited support

Genetic evidence dominant · Open Targets 0.28

View evidence synthesis (5)
Multiple MyelomaModerately supported
0.74
agreement 0.590.90
Clinical84%Literature16%

Open Targets aggregate 0.60 · 2 independent evidence families

Multiple SclerosisModerately supported
0.58
agreement 0.440.71
Genetic97%Literature3%

Open Targets aggregate 0.35 · 2 independent evidence families

Epstein-Barr Virus InfectionsModerately supported
0.53
agreement 0.400.67
Genetic99%Literature1%

Open Targets aggregate 0.32 · 2 independent evidence families

NeoplasmsModerately supported
0.53
agreement 0.380.69
Clinical76%Literature24%

Open Targets aggregate 0.40 · 2 independent evidence families

Rotator cuff syndromeLimited support
0.46
agreement 0.340.58
Genetic100%

Open Targets aggregate 0.28 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Multiple Myeloma0.60
Neoplasms0.40
Multiple Sclerosis0.35
Epstein-Barr Virus Infections0.32
Rotator cuff syndrome0.28
Miyoshi myopathy0.11
Autistic Disorder0.11
Immunoglobulin Light-chain Amyloidosis0.10
Breast Neoplasms0.09

Drug development

2 compounds recorded · 1 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (2)
AZINTUXIZUMAB VEDOTINPhase 1
ELOTUZUMABApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

AntibodiesStrong

Approved Drug and GO CC high conf support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (5)
AB · Approved DrugAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

TERMINATED · via elotuzumab · NCT04918147

ClinicalTrials.gov via the drug-target graph.

What's happening now

5

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-30

    64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

    Status changed to Active, not recruiting · ClinicalTrials.gov · via elotuzumab

  2. New publication2023-04-07
    A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.

    Clinical lymphoma, myeloma & leukemia · 2023 · 6 citations · Europe PMC · via elotuzumab

  3. New publication2018-08-10
    Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

    Frontiers in immunology · 2018 · 218 citations · Europe PMC · via elotuzumab

  4. Accelerated approval granted2016-05-11

    Accelerated approval: Empliciti (EMA)

    ema · regulatory · ema · via elotuzumab

  5. New publication2015-06-02
    Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

    The New England journal of medicine · 2015 · 1,019 citations · Europe PMC · via elotuzumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.